<![CDATA[FDA Approves Iberdomide Combo in Relapsed/Refractory Multiple Myeloma]]>
RegulatoryapprovedIberdomideDaratumumabHyaluronidasePositive
AI Analysis
Summary
The FDA granted accelerated approval to a combination of iberdomide plus daratumumab and hyaluronidase and dexamethasone for relapsed/refractory multiple myeloma, supported by Phase 3 EXCALIBER-RRMM trial data.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA accelerated approval of iberdomide plus daratumumab and hyaluronidase and dexamethasone combination
Importance:8/10
Sentiment:
0.95
FDA ApprovalAccelerated ApprovalMultiple MyelomaPhase 3EXCALIBER-RRMM
Related Companies
Read the original article
Published by Cancer Network on August 13, 2026 8:18 PM